Besins Healthcare #Urogenital_tract #Hormonal #HEALTH_CARE
Product description
Utrogestan capsules are used for disorders associated with progesterone deficiency.
Composition
Active substance: progesterone;
1 capsule contains micronized progesterone 100 mg or 200 mg;
Excipients: sunflower oil, soy lecithin, gelatin, glycerin, titanium dioxide (E 171), purified water.
Contraindications
- hypersensitivity to the components of the preparation;
- severe liver dysfunctions;
- suspected or confirmed breast or genital neoplasia;
- undiagnosed vaginal bleeding;
- unsuccessful or incomplete abortion;
- thrombophlebitis;
- thromboembolic disorders;
- cerebral hemorrhage;
- porphyria.
Mode of application
The duration of treatment depends on the nature of the disease.
In most cases, the average daily dose is 200-300 mg in 1 or 2 divided doses (200 mg in the evening, before bedtime, and 100 mg in the morning, if necessary).
In case of insufficiency of the luteal phase (premenstrual syndrome, menstrual irregularities, premenopause, fibrocystic breast disease): take within 10 days (usually from the 17th to the twenty-sixth day of the cycle, inclusive).
The use of progesterone after 36 weeks of pregnancy is not recommended.
Application features
Pregnant
The use of the preparation Utrogestan is not contraindicated during pregnancy, including in the first weeks. During the period of use of the preparation, not a single case of adverse effect of the preparation on the fetus was observed. When using the preparation in the second and third trimesters of pregnancy, monitoring of liver function is necessary.
The release of progesterone into breast milk has not been studied in detail. Therefore, its appointment should be avoided during breastfeeding.
Children
There are no clinical data on the use of the preparation in children.
Drivers
Transport drivers and machine operators: possible drowsiness and dizziness associated with taking the preparation internally. The use of capsules at bedtime avoids these unpleasant consequences. Cases of drowsiness and dizziness were observed only with oral administration of the preparation.
Overdose
Overdose symptoms can be manifested by symptoms of adverse reactions, including drowsiness, dizziness, euphoria, dysmenorrhea, decreased cycle duration, metrorrhagia.
In some individuals, the usual dose may be excessive due to the existing or secondary appearance of unstable endogenous progesterone secretion, hypersensitivity to the preparation, or very low concomitant blood estradiol levels.
In such cases, it is enough:
reduce the dose of progesterone or prescribe progesterone in the evening before bedtime for 10 days per cycle in case of drowsiness or fleeting dizziness;
postpone the start of treatment to a later date in the cycle in case of its reduction or bleeding;
check if the level of estradiol is sufficient in a patient who is receiving hormone replacement therapy in premenopausal women.
Side effects
Frequent (> 1/100; <1/10) side effects that were observed with oral administration:
disorders of the reproductive system and mammary glands: changes in menstruation, amenorrhea, intermittent bleeding;
violation of the central nervous system: headaches.
With vaginal use of the preparation, hypersensitivity reactions are possible, including burning, itching, hyperemia, as well as the appearance of oily discharge.
Interaction
In hormone therapy of menopause with estrogens, it is strongly recommended to prescribe progesterone no later than the twelfth day of the cycle.
If, in the treatment of the threat of premature birth, Utrogestan is combined with beta-adrenergic preparations, the doses of the latter can be reduced.
The simultaneous use of other preparations can change the metabolism of progesterone, causing an increase or decrease in the concentration of progesterone in plasma and, accordingly, lead to a change in the action of the preparation.
Storage conditions
Store at a temperature not exceeding 25 ° C, out of the reach of children.
Shelf life is 3 years.
$31.99 BUY ONLINE
MORE
No comments:
Post a Comment